Rick Modi, Affinia Therapeutics CEO (Affinia)

Look­ing to rein­vent those trou­bled AAVs you've been read­ing about, in­vestors back a $110M re­boot ef­fort

Next week, Affinia Ther­a­peu­tics will present four new ab­stracts at the Amer­i­can So­ci­ety of Gene and Cell Ther­a­py. Though they bear ob­scure and aca­d­e­m­ic names, they will pro­vide the first proof of con­cept for an ap­proach in­vestors have now poured $170 mil­lion in­to and that Affinia wants to get in the clin­ic next year.

Affinia, a 2019 spin­out from the lab of old Jim Wil­son pro­tégé Luk Van­den­berghe, an­nounced Mon­day that it raised a $110 mil­lion Se­ries B led by the biotech VC EcoR1 Cap­i­tal and the Tom Stey­er hedge fund Far­al­lon Cap­i­tal. Thir­teen oth­er in­vestors joined, in­clud­ing the blue-chip firms At­las, RA Cap­i­tal, Per­cep­tive Ad­vi­sors, Cas­din Cap­i­tal, F-Prime and GV.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.